Intec Pharma Ltd (NASDAQ:NTEC) gapped down prior to trading on Thursday . The stock had previously closed at $4.40, but opened at $4.62. Intec Pharma shares last traded at $4.95, with a volume of 22,829 shares trading hands.

Several research firms have commented on NTEC. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, April 20th. Maxim Group reissued a “buy” rating and set a $9.00 target price on shares of Intec Pharma in a research report on Tuesday, April 5th.

The firm’s market capitalization is $56.95 million. The company has a 50-day moving average of $4.52 and a 200-day moving average of $4.11.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.